All In Biotech

Drug Trial Radar · NCT06257537

Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

307

Actual

Start

Oct 1, 2024

Primary completion

Jun 26, 2026

Study completion Jun 26, 2026

Sponsor

Lead sponsor
ZetrOZ, Inc.Industry
Sponsor type
Industry
First posted
Feb 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the ability of long-duration low intensity therapeutic ultrasound (LITUS) to alleviate knee Osteoarthritis pain over a 24-week period. The primary objective of this study is to evaluate the analgesic effect of LITUS in subjects suffering from knee Osteoarthritis pain. Secondary objectives are to assess the ability of LITUS to improve joint function.

Conditions

  • Osteo Arthritis Knee
  • Arthritis

Interventions

  • Sustained Acoustic Device with 2.5% Diclofenac PatchDevice

    Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.

  • Sustained Acoustic Device with 0% Diclofenac PatchDevice

    Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.

  • 2.5% Diclofenac PatchesDrug

    Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.

  • SAM PatchOther

    Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From BaselineTime frame: Through study completion, average of 24 weeks.
  2. Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)Time frame: Through study completion, average of 24 weeks.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Orthopaedic Foundation

    Stamford, Connecticut

  • ZetrOZ Systems

    Trumbull, Connecticut

  • Cayuga Medical Center - Medical Pain Consultants

    Dryden, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.